ICT19G1

N/A

Report date: 2022/07/15 15:12:31

Base Information

Drug NameICT19G1

Drug Alias NameICT-19G1

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CD19

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesInnovative Cellular Therapeutics Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesInnovative Cellular Therapeutics Co Ltd

Inactive CompaniesN/A

Active IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A